Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
用于高血压、心力衰竭以及延迟和逆转高血压所引起的心脏病理变化。
Wellquest Clinical Research, Mumbai, Maharashtra, India
Wellquest Clinical Research, Mumbai, Maharashtra, India
University of Florida, Gainesville, Florida, United States
Research Site, Vaxjo, Sweden
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.